Cullinan Therapeutics, Inc. - COMMON STOCK (CGEM)

CUSIP: 230031106

Q2 2025 13F Holders as of 30 Jun 2025

Holder snapshot 7 signals
Share change
-2,064,371
Put/Call ratio
8652%
SEC-reported price per share
$7.53
Indexed holders
141
Value change
-$15,598,491
Number of buys
68
Open additional details 1 more signal available
Number of sells
67
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
65,102,625

Security key

230031106

Report period

Q2 2025

Indexed institutions

141

Top holders

10

Ownership snapshot

Top reported holders of CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FRANKLIN TEMPLETON INC
Disclosed value leader
Ansbert Gadicke
Comparable rows
1/15
Latest evidence
31 Mar 2025
13D/G 13F 3/4/5 Lead comparable stake: 3.8% 14 rows are not safely comparable across share classes. 13D/G row: FRANKLIN TEMPLETON INC Showing 1-6 of 15 holder rows.

Quick read

FRANKLIN TEMPLETON INC leads the comparable SEC ownership view at 3.8%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FRANKLIN TEMPLETON INC's linked filing trail.
Comparable ownership Top 1
FRANKLIN TEMPLETON INC 3.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FRANKLIN TEMPLETON INC
13D/G 13F
Franklin Resources, Inc. · Company
3.8%
Reported 13D/G · 30 Sep 2024
$17,836,873
2,191,262 shares
$0 30 Sep 2024
UBS Oncology Impact Fund L.P.
3/4/5
10%+ Owner
—
denominator unverified
$95,297,419
7,648,268 shares
— 16 Sep 2021
Morana Jovan-Embiricos
3/4/5
10%+ Owner
—
denominator unverified
$56,397,201
4,526,260 shares
— 24 Jun 2022
Vision Scs F2
3/4/5
10%+ Owner
—
denominator unverified
$55,775,322
4,476,350 shares
— 02 Aug 2022
F2 Bioscience I 2017 Ltd
3/4/5
10%+ Owner
—
denominator unverified
$55,209,813
4,430,964 shares
— 21 Jun 2022
BVF PARTNERS L P/IL
3/4/5
10%+ Owner
—
mixed-class rows
$799,446
94,161 shares
mixed-class rows
— 19 Jan 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
141
Shares
62,610,123
Indexed holders
141
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 indexed holders
145
Q2 2025 indexed holders
141
Indexed holder difference
-4
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .